ADMA BIOLOGICS INC (ADMA)
Health Care · Plasma-derived biologics and immunology products · NASDAQ
ADMA manufactures and markets FDA-approved plasma-derived immune globulin products for immunodeficient and infectious disease patients, operating an integrated plasma collection and fractionation platform.
What ADMA BIOLOGICS INC does
ADMA Biologics is a U.S. biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics for immunodeficient patients and those at risk for certain infectious diseases. The company operates two main business segments: ADMA BioManufacturing, which produces three FDA-approved products (ASCENIV and BIVIGAM for primary immunodeficiency treatment, and Nabi-HB for hepatitis B exposure), and ADMA BioCenters, which operates ten FDA-licensed source plasma collection facilities across the U.S. that supply raw material for manufacturing and generate revenue through third-party plasma sales. The company manufactures products at its FDA-licensed facility in Boca Raton, Florida with a peak processing capability of 600,000 liters annually.
Themes: ["Immunodeficiency disease treatment"]
Fundamentals
- Price$9.27 as of 2026-07-09 close
- Market cap$2.1B as of 2026-07-10
- 1-year return-48.6% as of 2026-07-09 close
- P/E12.84 as of 2026-07-10
- Net margin+32.4% as of 2026-07-10
- Gross margin+61.3% as of 2026-07-10
- ROE+39.0% as of 2026-07-10
- Debt / equity0.50 as of 2026-07-10
- Revenue growth (YoY)+11.0% as of 2026-07-10
- Revenue CAGR (3y)+49.0% SEC XBRL
- Beta0.79 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.